Skip to main content

Table 3 Relationship between the p73 (rs6695978 G > A) polymorphism and known clinicopathological variables of ovarian cancer

From: Polymorphisms in the p63 and p73 genes are associated with ovarian cancer risk and clinicopathological variables

Clinicopathological Variables All Genotype(%) A allele frequency Adjusteda
GG GA+AA P OR (95 % CI)
Age 308   0.948  
< 52 118 88 (74.6) 30 (25.4) 0.136 1.00 (ref)
≥52 190 146 (76.8) 44 (23.2) 0.137 2.87 (0.93-5.84)
Clinical stage 300     0.474  
I-II 92 69 (75.0) 23 (25.0) 0.131 1.00 (ref)
III-IV 208 158 (76.0) 50 (24.0) 0.142 1.30 (0.89-1.93)
Tumor histology 308   0.003  
Serous 196 150 (76.5) 46 (23.5) 0.128   1.00 (ref)
Mucinous 24 15 (62.5) 9 (37.5) 0.250 0.001 3.48 (1.15-6.83)
Endometrioid 22 17 (77.3) 5 (22.7) 0.114 0.337 2.25 (0.96-4.44)
Mixed/other 66 52 (78.8) 14 (21.2) 0.136 0.597 0.93 (0.76-1.19)
Degree of differentiation 246   0.005  
High 28 22 (78.6) 6 (21.4) 0.107   1.00 (ref)
Medium 82 65 (79.3) 17 (20.7) 0.104 0.827 1.15 (0.86-1.69)
Low 136 98 (72.1) 38 (27.9) 0.162 0.003 1.87 (1.03-3.47)
Tumor behavior 294   0.838  
Borderline 48 37 (77.1) 11 (22.9) 0.125 1.00 (ref)
Invasive 246 191 (77.6) 55 (22.4) 0.122 0.91 (0.79-1.03)
Lymph node statusb 176   0.010  
Negative 62 50 (80.6) 12 (19.4) 0.105 1.00 (ref)
Positive 114 83 (72.8) 31 (27.2) 0.154 1.69 (1.14-2.75)
ERc 183   0.002  
Negative 42 36 (85.7) 6 (14.3) 0.095 1.00 (ref)
Positive 141 100 (70.9) 41 (29.1) 0.163 2.72 (1.38-4.81)
PRc 171   0.329  
Negative 66 49 (74.2) 17 (25.8) 0.144   1.00 (ref)
Positive 105 81 (77.1) 24 (22.9) 0.129   1.43 (0.76-2.32)
  1. a Logistic regression model adjusted for age, BMI, number liveborn, oral contraceptive use, cigarette smoking, ovarian cancer family history.
  2. b For advanced ovarian cancer patients, in terms of primary cytoreductive surgery, whether to simultaneously apply pelvic and para-aortic lymph node dissection is controversial. The general consensus that pelvic and para-aortic lymph node dissection does not increase the 5-year survival rate and improve prognosis has been widely accepted. Thus, some patients involved in our study only underwent primary cytoreductive surgery without pelvic and para-aortic lymph node dissection. The data regarding lymph node status in patients were partially missing.
  3. c Unlike breast cancer and endometrial cancer, the significance of ER and PR in the clinical treatment and prognosis of ovarian cancer is also valuable and disputed. Meanwhile, combined with the economic condition of the patients, some cases did not undergo ER and PR immunohistochemical analyses.
  4. All statistical tests were two-sided with a significance level of P ≤ 0.05.